- $669.93m
- $346.09m
Brief: Aura Biosciences Announces Appointment Of Teresa Bitetti To Board Of Directors
Aura Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary
Aura Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Aura Biosciences FY Operating Income USD -96.116 Million
Brief: Aura Biosciences Q3 Operating Expenses USD 23.232 Million
Aura Biosciences rises on early-stage data for bladder cancer drug
Brief: Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration Of Bel-Sar In Patients With Non-Muscle-Invasive Bladder Cancer (NMIBC) In Ongoing Phase 1 Trial
Brief: Aura Biosciences Appoints Amy Elazzouzi As CFO
U.S. STOCKS ON THE MOVE-Unity Software, Viking Holdings, Adobe
U.S. STOCKS ON THE MOVE-Gold miners, silver miners, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Fulcrum Therapeutics, Summit Therapeutics, Signet Jewelers
Aura Biosciences rises after data from mid-stage study of cancer treatment
Brief: Aura Biosciences Reports Positive Phase 2 End Of Study Results Evaluating Bel-Sar As A First-Line Treatment For Early-Stage Choroidal Melanoma
Aura Biosciences Inc reports results for the quarter ended in January - Earnings Summary
Brief: Aura Biosciences Q2 Operating Expenses USD 22.762 Million
Aura Biosciences Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Aura Biosciences Q1 Net Income USD -19.706 Million
Aura Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Aura Biosciences Files For Mixed Shelf Offering Of Up To $350 Mln